What happened?
A multi-model assessment from ECDC models the potential impact of newborn and infant RSV immunisation on hospital admissions across the EU/EEA. The report notes newborns have the highest per-capita RSV hospitalisation risk and estimates RSV causes roughly 250,000 paediatric hospital admissions annually in the EU/EEA, with 7–52% of paediatric respiratory admissions attributed to RSV.
Why does it matter?
New extended half-life monoclonal antibodies and a maternal vaccine have EU authorisations (nirsevimab 2022, clesrovimab 2026, maternal vaccine 2023). The modelling explores how these passive and maternal immunisation options could reduce infant hospital burden, inform national decisions and ease seasonal pressure on paediatric services.
How to interpret the evidence
The assessment models population-level effects but acknowledges uncertainty in country-specific epidemiology, uptake, timing and long-term effectiveness. Results are intended to inform national policy; they do not presume uniform availability or implementation in all EU/EEA states, including Malta. Local decision-makers should consider local burden, costs and logistics.
What remains uncertain?
This is modelling, not a clinical guideline. It does not prescribe individual treatment, guarantee products will be available in every country, or replace national vaccine policy decisions. Estimated reductions are scenario-based and sensitive to uptake, timing and real-world effectiveness.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.